GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Shiller PE Ratio

NEO (NeoGenomics) Shiller PE Ratio : (As of Dec. 13, 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Shiller PE Ratio Historical Data

The historical data trend for NeoGenomics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Shiller PE Ratio Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeoGenomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeoGenomics's Shiller PE Ratio

For the Diagnostics & Research subindustry, NeoGenomics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Shiller PE Ratio falls into.



NeoGenomics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

NeoGenomics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, NeoGenomics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.14/133.0289*133.0289
=-0.140

Current CPI (Sep. 2024) = 133.0289.

NeoGenomics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 0.020 99.070 0.027
201503 -0.010 99.621 -0.013
201506 -0.003 100.684 -0.004
201509 -0.002 100.392 -0.003
201512 -0.030 99.792 -0.040
201603 -0.070 100.470 -0.093
201606 -0.070 101.688 -0.092
201609 -0.070 101.861 -0.091
201612 -0.180 101.863 -0.235
201703 -0.050 102.862 -0.065
201706 -0.030 103.349 -0.039
201709 -0.090 104.136 -0.115
201712 0.030 104.011 0.038
201803 -0.030 105.290 -0.038
201806 0.070 106.317 0.088
201809 0.020 106.507 0.025
201812 0.004 105.998 0.005
201903 -0.030 107.251 -0.037
201906 0.020 108.070 0.025
201909 0.020 108.329 0.025
201912 0.060 108.420 0.074
202003 -0.070 108.902 -0.086
202006 -0.060 108.767 -0.073
202009 0.020 109.815 0.024
202012 0.130 109.897 0.157
202103 -0.190 111.754 -0.226
202106 0.590 114.631 0.685
202109 -0.170 115.734 -0.195
202112 -0.340 117.630 -0.385
202203 -0.400 121.301 -0.439
202206 -0.280 125.017 -0.298
202209 -0.300 125.227 -0.319
202212 -0.180 125.222 -0.191
202303 -0.250 127.348 -0.261
202306 -0.190 128.729 -0.196
202309 -0.150 129.860 -0.154
202312 -0.110 129.419 -0.113
202403 -0.210 131.776 -0.212
202406 -0.150 132.554 -0.151
202409 -0.140 133.029 -0.140

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (NAS:NEO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


NeoGenomics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913